<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Document</title>
    <!-- Font Awesome -->
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.9.0/css/all.min.css"
        integrity="sha512-q3eWabyZPc1XTCmF+8/LuE1ozpg5xxn7iO89yfSOd5/oKvyqLngoNGsx8jq92Y8eXJ/IRxQbEC+FGSYxtk2oiw=="
        crossorigin="anonymous" referrerpolicy="no-referrer" />
    <!-- Bootstrap CSS -->
    <link rel="stylesheet" href="css/bootstrap.min.css">
    <!-- Custom CSS -->
    <link rel="stylesheet" href="css/style.css">
</head>

<body>

    <div class="main_page5 fixedHeight">
        <div class="nav_orange">
            <div class="nav_orange_left">
                <h4 class="GothamBook mb-0"><strong>Terpos et al. Greece, UK, Czech NPP Real-world study:</strong> <br> a retrospective combined analysis of Ixazomib (NINLARO) + Rd in RRMM<sup>1</sup></h4>
            </div>
            <div class="nav_orange_right">
                <img src="img/logo_orange.png" alt="">
            </div>
        </div>
        <!-- page 5 middle box --> 
            <div class="page5_middle_box page8_middle_box mb-4 bigLineHight">
                <div class="page8_middle_left">
                    <h4 class="txt_orange GothamBook mt-1 mb-4">STUDY <strong class="GothamBold">DESIGN:</strong></h4>
                    <p class="d-flex align-items-start dark_secondary GothamBook fs-14 mb-2"><img class="mt-2 me-2" src="img/li_1.svg" alt=""> <span>Retrospective analysis of patients with RRMM from Greece, UK, and Czech Republic participating in a named-patient programme of compassionate use of Ixazomib (NINLARO) + Rd<sup>1</sup></span></p>
                    <p class="d-flex align-items-start dark_secondary GothamBook fs-14 mb-2"><img class="mt-2 me-2" src="img/li_1.svg" alt=""> <span>155 patients treated at 12 different clinical centres (3 in Greece, 7 in the UK, and 2 in the Czech Republic) between Dec 2015 and Oct 2017<sup>1</sup></span></p>
                </div>
                <div class="page8_middle_right">
                    <h4 class="txt_orange GothamBook mt-1 mb-4">STUDY <strong class="GothamBold">ENDPOINTS:</strong></h4>
                    <p class="d-flex align-items-start dark_secondary GothamBook fs-14 mb-2"><img class="mt-2 me-2" src="img/li_1.svg" alt=""> <span>Primary endpoint was to determine the overall response rate (ORR) with Ixazomib (NINLARO) + Rd<sup>1</sup></span></p>
                    <p class="d-flex align-items-start dark_secondary GothamBook fs-14 mb-2"><img class="mt-2 me-2" src="img/li_1.svg" alt=""> <span>Secondary endpoints included PFS (overall and within patient subgroups) and safety<sup>1</sup></span></p>
                </div>
            </div>
            <div class="page5_middle_box page8_middle_box_p mb-1">
                <p class="GothamBook dark_secondary fs-11"><span class="fs-11">Study limitations:</span> Real-world analyses are often nonrandomised, observational, retrospective studies that may have unobserved
                    treatment selection biases as well as other limitations that should be considered when comparing results with clinical trials. Outcomes
                    should be interpreted with caution due to small sample size, limited follow-up, and limited maturity of data.<sup>1</sup></p>
            </div>
        <!--  -->
            <div class="page5_middle_box pt-4 mb-5" style="margin-top: 13px;">
                <div class="page5_btns_sm">
                    <a href="../page22/index.html" class="text-uppercase"><p class="mb-0 position-relative">PFS</p></a>
                    <a href="../page28/index.html" class="text-uppercase"><p class="mb-0 position-relative">PRE-TREATED PFS</p></a>
                    <a href="../page26/index.html" class="text-uppercase"><p class="mb-0 position-relative">ORR</p></a>
                    <a href="../page16/index.html" class="text-uppercase"><p class="mb-0 position-relative">PATIENT BASELINE CHARACTERISTICS</p></a>
                </div>
            </div>

            <div class="page5_middle_box page5_p_sm w-100 mb-4">
                <p class="GothamLight">NPP = named-patient programme; ORR = overall response rate; PFS = progression-free survival; Rd = REVLIMIDÂ® (lenalidomide) + dexamethasone; RRMM = relapsed/refractory multiple myeloma; UK = United Kingdom.</p>
            </div>


            <div class="footer_page5">
                <div class="d-flex align-items-end">
                    <div class="page5_btns_md">
                        <a href="../page5/index.html"><p class="mb-0 position-relative">MM1 study design</p></a>
                        <a href="../page6/index.html"><p class="mb-0 position-relative">MM1 patient baseline characteristics</p></a>
                        <a href="../page8/index.html"><p class="mb-0 position-relative">RWE study Hajek et al.</p></a>
                        <a href="../page15/index.html"><p class="mb-0 position-relative">RWE study Terpos et al.</p></a>
                        <a href="../page11/index.html"><p class="mb-0 position-relative">RWE study Chari et al.</p></a>
                        <a href="../page18/index.html"><p class="mb-0 position-relative">RWE study Minarik et al.</p></a>
                        <a href="../page21/index.html"><p class="mb-0 position-relative">MM1 PFS</p></a>
                        <a href="../page23/index.html"><p class="mb-0 position-relative">MM1 PFS in patients with high-risk cytogenetics</p></a>
                        <a href="../page25/index.html"><p class="mb-0 position-relative">MM1 response rate</p></a>
                        <a href="../page28/index.html"><p class="mb-0 position-relative">MM1 PFS in <br> pre-treated patients</p></a>
                        <a href="../page31/index.html"><p class="mb-0 position-relative">MM1 safety data</p></a>
                        <a href="../page34/index.html"><p class="mb-0 position-relative">Dosing</p></a>
                        <a href="../page36/index.html"><p class="mb-0 position-relative">Summary</p></a>
                        <a href="../page38/index.html"><p class="mb-0 position-relative">MM6 data</p></a>
                        <a></a>
                    </div>
                    <div class="footer_inner_nav1 position-static ms-auto bg-transparent p-0">
                        <ul>
                            <li>
                                <a href="../page4/index.html"><img src="img/page_1_footer_icon_1.svg" alt=""></a>
                            </li>
                            <li>
                                <a href="https://onetakeda.app.box.com/s/reg7tviee8telgupc6cccshjet2wqqqh" target="_blank" class="text-uppercase">pi</a>
                            </li>
                            <li>
                                <a href="../page17/index.html" class="text-uppercase">ref</a>
                            </li>
                        </ul>
                    </div>
                </div>
            </div>
    </div>

</body>

</html>